- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01809236
Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion (FALCON)
March 25, 2014 updated by: Chengdu Kanghong Biotech Co., Ltd.
An Open Label, Single Arm Clinical Study of Intravitreal Injection of Conbercept in Patients With Maculae Edema Secondary to Retinal Vein Occlusion (the FALCON Study)
This is a Phase II, single arm, open label clinical trial.
60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study.
The study included a fixed treatment period (3 months) and a PRN period (6 months).
In the fixed treatment period patients will receive 3 consecutive monthly intravitreal of 0.5 mg Conbercept.
In the PRN period, patients are monthly visited and retreatment will be needed according to the retreatment criteria pre-specified.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Beijing Tongren Hospital affiliated to Capital Medical University
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325027
- The Affiliated Eye Hospital of WMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability and willingness to provide signed Informed Consent Form.
- Age ≥ 18, both male and female。
Ocular Inclusion Criterion (Study Eye):
- Diagnosis of Foveal center-involved macular edema due to RVO (both CRVO and BRVO) within 6 months.
- Best corrected visual acuity (BCVA) letter score in the study eye of ≤ 73(Snellen equivalents 20/40).
- Central retinal thickness by OCT in the study eye ≥ 320 μm.
Exclusion Criteria:
- Brisk afferent pupillary defect.
- History of any anti-VEGF treatment in the study and/or system within 6 months before enrollment, and/or in the fellow eye within 3 month.
- History of intraocular and/or peri-ocular corticosteroid use in the study eye within 3 months, and/or history of use steroids systemic (p.o., i.m., i.v.) within 1 month.
- Any active infection involving the ocular including blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis in either eye.
- Any inflammatory cells detected in the anterior chamber and/or vitreous in the study eye.
- Presence of non-RVO disease, in the opinion of the investigator, might cause macular edema, such as AMD (wet or dry), diabetes retinopathy, uveitis etc.
- Neovascular change in the study eye and/or neovascularization of the iris or neovascular glaucoma in study eye at baseline.
- Patients with substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by equal or more than 3 lines or medicine or surgery treatment are needed in the study eye within 4 months.
- Patients diagnosed with systemic immune diseases and any uncontrolled clinical disease.
- Pregnant or nursing women.
- Patients need to exclude in the opinion of investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 0.5 mg Conbercept
patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.
|
intravitreal injection of 0.5 mg Conbercept
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change from baseline in BCVA
Time Frame: 3-month
|
3-month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change from baseline in BCVA
Time Frame: baseline to 9-month
|
baseline to 9-month
|
Mean change from baseline in central retinal thickness
Time Frame: baseline to 9-month
|
baseline to 9-month
|
Mean injection times
Time Frame: baseline to 9-month
|
baseline to 9-month
|
Mean change from baseline in Macular edema volume and other anatomical character in the study eye
Time Frame: baseline to 9-month
|
baseline to 9-month
|
Rate of adverse event
Time Frame: 3-month and 9-month
|
3-month and 9-month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (ACTUAL)
November 1, 2013
Study Completion (ANTICIPATED)
March 1, 2014
Study Registration Dates
First Submitted
March 11, 2013
First Submitted That Met QC Criteria
March 11, 2013
First Posted (ESTIMATE)
March 12, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
March 27, 2014
Last Update Submitted That Met QC Criteria
March 25, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KHSWKH902008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Vein Occlusion
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
Palo Alto Medical FoundationTerminatedCentral Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
Justis EhlersRegeneron PharmaceuticalsCompletedCentral Retinal Vein Occlusion | Diabetic Macular Edema | Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hoffmann-La RocheChugai PharmaceuticalCompletedCentral Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein OcclusionUnited States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
-
The Emmes Company, LLCNational Eye Institute (NEI); University of California, DavisActive, not recruitingCentral Retinal Vein OcclusionUnited States
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenCompleted
Clinical Trials on Conbercept
-
Jiao MingfeiUnknownIdiopathic Choroidal NeovascularizationChina
-
Chengdu Kanghong Biotech Co., Ltd.UnknownChoroid Neovascularization Secondary to Degenerative MyopiaChina
-
Chengdu Kanghong Biotech Co., Ltd.CompletedMacular Edema | Branch Retinal Vein OcclusionChina
-
Shanghai Eye Disease Prevention and Treatment CenterShanghai General Hospital, Shanghai Jiao Tong University School of MedicineRecruiting
-
Sun Yat-sen UniversityUnknownCircumscribed Choroidal HaemangiomaChina
-
Chengdu Kanghong Biotech Co., Ltd.UnknownVery Low Vision Secondary to Wet Age-related Macular DegenerationChina
-
Tianjin Medical University Eye HospitalCompletedEarly Proliferative Diabetic Retinopathy
-
Chengdu Kanghong Biotech Co., Ltd.UnknownPolypoidal Choroidal Vasculopathy (PCV)China
-
Chongqing Medical UniversityUnknownUveitis | Choroidal Neovascularization
-
Peking University Third HospitalRecruitingProliferative Diabetic RetinopathyChina